FDA approval

$TPB stock plunged 15.5% as FDA hesitation on nicotine pouch approvals threatens Fre brand growth, which rose 266% YoY but now faces regulatory headwinds.

$INO faces securities fraud lawsuit alleging false statements about INO-3107 regulatory timeline and CELLECTRA device manufacturing. Stock fell 24.45% in December 2025 after FDA rejected accelerated review.

Class action lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug's clinical strength and FDA approval prospects.

$CORT faces securities fraud lawsuit alleging false statements about relacorilant's FDA approval status. Investors from October 2024-December 2025 can join class action with Schall Law Firm.

Securities class action filed against $QURE for alleged misrepresentation regarding Pivotal Study design and FDA approval timeline for Huntington's disease treatment.

uniQure faces securities class action over alleged FDA disclosure failures; investors have until April 13, 2026, to join litigation seeking damages.

Inovio shareholders with $100K+ losses must meet April 7 deadline to join securities lawsuit alleging false statements about CELLECTRA device and INO-3107 FDA timeline.

Esperion completes acquisition of Corstasis, adding Enbumyst, first FDA-approved nasal spray loop diuretic, to expand its cardiovascular product portfolio.

Esperion closes Corstasis acquisition, gaining FDA-approved Enbumyst nasal spray loop diuretic for heart failure treatment, leveraging existing cardiovascular commercial infrastructure.

Corcept Therapeutics faces class action lawsuit alleging misrepresentation of relacorilant clinical trial data and FDA approval prospects. Investors from Oct 2024-Dec 2025 may seek compensation.

Soligenix's HyBryte demonstrated superior efficacy versus Valchlor in treating cutaneous T-cell lymphoma, with 60% versus 20% success rates at 12 weeks, backed by $2.6M FDA grant.

Priovant initiates Phase 2b/3 trial for brepocitinib in lichen planopilaris, marking fourth indication; dermatomyositis FDA decision expected Q3 2026.

Eli Lilly stock surged 4% after FDA approval of Foundayo, its oral weight-loss pill priced at $149/month, competing with Novo Nordisk's Wegovy.

Turning Point Brands stock drops 14% after FDA scientists express safety concerns about nicotine pouches, threatening approval of key products.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

Ultragenyx faces securities fraud lawsuit after setrusumab Phase 3 failure triggered 42% stock decline. Lead plaintiff applications due April 6, 2026.

Corcept Therapeutics faces securities class action after FDA rejected relacorilant, causing 50% stock collapse. Investors have until April 21 to file claims.

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.

Novo Nordisk launches Wegovy subscription program with monthly pricing from $249-$329, offering up to $1,200 annual savings via telehealth partners.